Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
70
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

111
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
111
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

93
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
93
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

386
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
386
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

72
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
72

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evolving Concepts of Treatment Targets for Primary Biliary Cholangitis: A Global Perspective.

The American journal of gastroenterology·2026
Same author

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Hepatology communications·2026
Same author

Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America-A 5-Year Analysis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Impact of Alkaline Phosphatase Normalization on Complication-Free Survival in Primary Biliary Cholangitis.

The American journal of gastroenterology·2026
Same author

Nebokitug, an Anti-chemokine (C-C Motif) Ligand 24 Monoclonal Antibody, in Patients With Primary Sclerosing Cholangitis: A Phase 2 Study.

The American journal of gastroenterology·2025

Related Experiment Video

Updated: Jun 4, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

15.5K

Primary biliary cholangitis: Personalizing second-line therapies.

Cynthia Levy1,2, Christopher L Bowlus3

  • 1Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.

Hepatology (Baltimore, Md.)
|December 21, 2024
PubMed
Summary
This summary is machine-generated.

Primary biliary cholangitis (PBC) treatment involves ursodeoxycholic acid, with new agents like obeticholic acid, elafibranor, and seladelpar offering improved outcomes for patients needing second-line therapy.

Keywords:
FXRPPARPrecision MedicineSecond-line therapiesTreatment

More Related Videos

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

15.5K
Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts
09:55

Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts

Published on: May 16, 2020

3.8K

Related Experiment Videos

Last Updated: Jun 4, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

15.5K
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

15.5K
Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts
09:55

Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts

Published on: May 16, 2020

3.8K

Area of Science:

  • Hepatology
  • Immunology
  • Pharmacology

Background:

  • Primary biliary cholangitis (PBC) is an autoimmune liver disease affecting bile ducts, primarily in middle-aged women.
  • Ursodeoxycholic acid (UDCA) is the standard first-line treatment, delaying progression but not alleviating symptoms.
  • Many patients require second-line therapy due to inadequate response to UDCA.

Purpose of the Study:

  • To review patient factors influencing the decision to initiate second-line therapy for PBC.
  • To discuss the personalized selection of second-line agents based on efficacy and tolerability.
  • To highlight recent advances in PBC treatment beyond UDCA.

Main Methods:

  • Review of current literature on PBC pathophysiology and treatment guidelines.
  • Analysis of clinical trial data for second-line agents in PBC.
  • Discussion of patient characteristics relevant to treatment selection.

Main Results:

  • Second-line agents, including obeticholic acid, elafibranor, seladelpar, bezafibrate, and fenofibrate, demonstrate biochemical improvements in UDCA-inadequately responding PBC patients.
  • Obeticholic acid improves liver biochemistries but can cause pruritus.
  • PPAR agonists like elafibranor and seladelpar show promise, potentially improving pruritus alongside biochemical markers.

Conclusions:

  • Personalized treatment strategies are crucial for optimizing PBC management.
  • Selecting second-line agents requires careful consideration of individual patient needs, including symptom burden and potential side effects.
  • Newer agents offer improved therapeutic options for patients with advanced or refractory PBC.